The Vitamin–Liver Cancer Link I Didn’t Expect

JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT] Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2 HEALTH AUTONOMY [COURSE] Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy JOIN THE COMMUNITY Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2 EMAIL LIST 1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6 HIRE ME FOR CONSULTING: Consulting: https://bit.ly/3dmUl2H Created with Biorender 0:00 - Introduction 0:50 - Vitamin K and Liver Cancer: Why? 2:55 - 11 Studies say Yes or No? 4:36 - Biggest Study on the Block Disagrees 6:05 - I Have Liver Cancer, Still Applies? 7:05 - Never Had Liver Cancer, Still Applies? Vitamin K on Cardiovascular Disease:    • We’ve been lied to about Vitamin K   References^ *Full Funding/Conflicts are provided in the free article (found in email list and Physionic Community Article Library) [Study 717] Haruna Y, Yakushijin T, Yamakawa M, Nakazawa T. Anticancer effects of vitamin K combined with transarterial chemoembolization in hepatocellular carcinoma, a randomized controlled trial. Br J Cancer. 2025;132:1141-1147. doi:10.1038/s41416-025-03022-4 [Study 718] Haruna Y, Yakushijin T, Kawamoto S, et al. Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: a phase II, randomized study. Cancer Med. 2021;10:914-922. doi:10.1002/cam4.3674 [Study 719] de Moraes FCA, Sano VKT, Pereira CRM, Barros JCM, Burbano RMR. Vitamin K2 supplementation and clinical outcomes in hepatocellular carcinoma patients: a meta-analysis with trial sequential analysis. Nutr Cancer. 2026;78(3):208-220. doi:10.1080/01635581.2025.2600102 . [Study 720] Habu D, Shiomi S, Tamori A, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA. 2004;292(3):358-361. Funding/Conflicts: Public Funding: From the study, the work was supported in part by a grant from Japan’s Ministry of Health, Labor, and Welfare; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, no industry funding source was reported, and no author conflicts of interest were reported in the accessible study record. [Study 721] Hosho K, Okano J, Koda M, Murawaki Y. Vitamin K2 has no preventive effect on recurrence of hepatocellular carcinoma after effective treatment. Yonago Acta Med. 2008;51:95-99. [Study 722] Ishizuka M, Kubota K, Shimoda M, Kita J, Kato M, Park KH, et al. Effect of menatetrenone, a vitamin K2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial. Anticancer Res. 2012;32:5415-5420. [Study 723] Mizuta T, Ozaki I, Eguchi Y, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer. 2006;106(4):867-872. doi:10.1002/cncr.21667 [Study 724] Yoshida H, Shiratori Y, Kudo M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology. 2011;54(2):532-540. [Study 725] Yoshiji H, Noguchi R, Toyohara M, et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol. 2009;51(2):315-321. doi:10.1016/j.jhep.2009.04.011 Please use the following link to submit your critique: https://bit.ly/PhysionicCritique Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.